HWK-016

MUC16-directed antibody-drug conjugate · Whitehawk Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HWK-016, covering 2026-03-13 to 2026-03-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. [Phase 1]